Drucker Wealth 3.0 LLC Has $795,000 Stock Holdings in Eli Lilly and Company $LLY

Drucker Wealth 3.0 LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 36.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,010 shares of the company’s stock after purchasing an additional 272 shares during the period. Drucker Wealth 3.0 LLC’s holdings in Eli Lilly and Company were worth $795,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Williams & Novak LLC acquired a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $334,000. Eastern Bank raised its stake in Eli Lilly and Company by 14.1% during the 2nd quarter. Eastern Bank now owns 123,674 shares of the company’s stock valued at $96,408,000 after purchasing an additional 15,293 shares during the period. Lmcg Investments LLC raised its stake in Eli Lilly and Company by 12.4% during the 2nd quarter. Lmcg Investments LLC now owns 11,312 shares of the company’s stock valued at $8,818,000 after purchasing an additional 1,249 shares during the period. Zullo Investment Group Inc. raised its stake in Eli Lilly and Company by 5.4% during the 2nd quarter. Zullo Investment Group Inc. now owns 1,649 shares of the company’s stock valued at $1,286,000 after purchasing an additional 85 shares during the period. Finally, First Fiduciary Investment Counsel Inc. acquired a new stake in Eli Lilly and Company during the 2nd quarter valued at $390,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jamere Jackson acquired 200 shares of the stock in a transaction dated Friday, August 8th. The shares were bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 2.6%

NYSE:LLY opened at $833.08 on Friday. The stock’s 50 day moving average price is $742.42 and its 200 day moving average price is $766.36. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The company has a market capitalization of $788.47 billion, a P/E ratio of 54.45, a P/E/G ratio of 1.19 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the business posted $3.92 EPS. Eli Lilly and Company’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. Guggenheim upped their target price on Eli Lilly and Company from $875.00 to $948.00 and gave the company a “buy” rating in a report on Wednesday. Leerink Partners reiterated a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Finally, HSBC upped their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $948.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.